CADL is a single-asset pre-commercial biotech preparing a Q4 2026 BLA for aglatimagene besadenovec (CAN-2409), a replication-defective adenovirus + radiation combination for localized prostate cancer. The Q1 2026 10-Q filed May 14 — one day before the AUA plenary oral presentation — contained one major milestone update and one forensic gap visible only if you cross-reference FDA databases against the filing. The stock has run 78% in the last month to $8.77. Most of the obvious alpha has propagated to price; the non-obvious piece has not.

What the filing says

Exhibit 10.1 is a First Amendment to the Master Production Services Agreement with SAFC Carlsbad, Inc. (MilliporeSigma / Merck KGaA), effective April 9, 2026. The amendment explicitly authorizes PPQ batches "manufactured under the Agreement prior to the Effective Date" for commercial launch and sale. PPQ (process performance qualification) is the last major manufacturing prerequisite for BLA filing. It is done. CDMO identity — previously an open gap — is now known. SAFC is a top-tier viral vector facility; the relationship dates to November 2022.

BLA Q4 2026 is reconfirmed with no hedging language. A new catalyst is disclosed: Q3 2026 "novel immunological biomarker data" — not previously in the deck. NSCLC's FDA end-of-phase-2 meeting is complete, with the agency explicitly acknowledging the Phase 3 can serve as registrational; trial initiation Q2 2026.

Q1 operating cash outflow was $18.0M, annualizing to ≈$72M against prior $50-65M full-year guidance — clinical R&D and commercial readiness spend stepped up materially. Cash at $194.8M; runway into Q1 2028 reconfirmed.

A new risk factor was added this quarter: the RTW Purchase Agreement covenants limit CADL's ability to take on debt, out-license assets, or grant liens. RTW will receive a lien on IP at closing. The "specified date" by which FDA must approve for RTW to pay the $100M remains undisclosed.

What the market thinks

Stock $8.77, +78% in 30 days. Market cap ≈$600M. RSI 86.7 (overbought). Short interest 26%, 8.9 days to cover. Options P/C (OI) 0.04 — 22.7x calls vs puts. ATM IV 107%, 103rd percentile. Analyst mean target $18.88 (range $7-26). Director Paul Manning made an open-market $3.0M purchase at $5.45 on February 23 — the conviction signal that preceded the run.

Options-implied probabilities at the October expiry (152d): P(stock<$7) = 24%; P(stock<$4) = 8%. A probability-weighted scenario tree built from the worldview gives P(stock<$7) = 47% and P(stock<$4) = 24%. At $4.94 in early April, the market was more bearish than the filing-supported probabilities. At $8.77 today, the market is more bullish than them. The mispricing has reversed direction.

Fair value (probability-weighted, 18mo horizon): ≈$12. Expected return at $8.77: +25% to +50% (point estimate ≈37%, ≈23% annualized). Idio Sharpe at current price: ≈0.32 — below the 0.5 threshold for fresh sizing under proportional allocation.

Why the gap exists

The bullish piece — PPQ completion and AUA anticipation — has propagated to options and analyst targets. The bearish piece has not.

SAFC Carlsbad received an FDA Form 483 on August 14, 2025 citing failure to follow or establish written procedures for manufacturing equipment maintenance, with observations covering 2022-2024 — exactly the window when CADL's PPQ batches were manufactured. The 483 is on SAFC's FDA record, not in CADL's filing, and legally need not be disclosed by CADL (it is the CDMO's regulatory record). Most sell-side biotech models do not cross-reference FDA inspection databases against client filings. Base rate for procedural equipment-maintenance 483s without product-quality findings is ≈85% Voluntary Action Indicated; ≈15% escalation to warning letter or OAI. Tail risk is real but bounded.

Risks (ranked)

1. AUA data miss this weekend. Time-to-metastasis null or subgroup heterogeneity. DFS surrogate weakness (ICECaP R²=0.73 vs MFS 0.92) leaves CAN-2409 vulnerable to FDA second-guessing. Downside ~−50% to pre-run levels.
2. SAFC 483 escalates to warning letter or OAI before CADL's BLA pre-approval inspection (mid-2027). BLA delayed 12-18 months. Downside ~−45%.
3. Clinical CRL on DFS surrogate methodology. Downside ~−60%.
4. RTW $100M royalty deadline still undisclosed ("a specified date"); covenant trap if BLA slips.

Catalysts

What would change our mind

• SAFC EIR posted as VAI before BLA: tail risk removed, fair value rises 10-15%.
• AUA spectacular (time-to-metastasis HR <0.5, subgroups uniformly positive): multiple expansion justified.
• Multiple insider P-code purchases in next 60 days: conviction signal stacks.
• RTW deadline disclosed as 2029+: contingent royalty re-rates as high-probability cash.
• SAFC warning letter or OAI: thesis breaks on inspection track.
• AUA subgroup heterogeneity or null time-to-metastasis: DFS surrogate validity cracks; reassess approval probability.
• Recent NSCLC PD-L1-low Phase 3 failures (TACTI-004 futility, LATIFY 2026) compress the NSCLC option, but the prostate BLA thesis is decoupled from this.

Position implications (not a recommendation)

Entry quality at $8.77: fair. Probability-weighted expected return is positive but the Sharpe is below threshold — diluted by the 78% run. The trade was at $5; the filing caught it; the tape caught up. Held positions from $5-6 retain compelling risk-adjusted return. Fresh entry at current price is paying for what already moved. The only catalyst that matters in the next 72 hours is AUA, and at IV 107% the binary is priced.

Evidence